Investigating the role of PEA15 in liver cancer and its treatment options
PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATION
This study is looking at how a protein called PEA15 affects liver cancer, hoping to find new ways to treat it and help patients who might not respond well to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10771944 on NIH RePORTER |
What this research studies
This research focuses on understanding how the protein PEA15 contributes to the development of liver cancer, known as hepatocellular carcinoma (HCC). By analyzing genetic and epigenetic changes associated with HCC, the study aims to identify new therapeutic targets and improve treatment strategies. Patients may benefit from insights gained about resistance to current treatments, such as sorafenib, which has limited effectiveness. The research employs advanced proteomic analysis to uncover potential new pathways for intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with hepatocellular carcinoma or those at high risk for developing liver cancer.
Not a fit: Patients with liver cancer who are already receiving effective treatment or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for liver cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting specific proteins in cancer treatment, suggesting that this approach could yield valuable insights and potential breakthroughs.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lee, Ju-Seog — University of Tx Md Anderson Can Ctr
- Study coordinator: Lee, Ju-Seog
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.